Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy.

Zarifa A, Albittar A, Kim PY, Hassan S, Palaskas N, Iliescu C, Durand JB, Lopez-Mattei J.

Curr Opin Cardiol. 2019 Jul;34(4):441-450. doi: 10.1097/HCO.0000000000000641.

PMID:
31082852
2.

Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors.

Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, Naing A, Le H, Hassan SA, Karimzad K, Mouhayar E, Kim P, Lopez-Mattei J, Thompson K, Yusuf SW, Iliescu C.

Am J Cardiol. 2019 Apr 15;123(8):1351-1357. doi: 10.1016/j.amjcard.2019.01.013. Epub 2019 Jan 25.

PMID:
30765065
3.

Refractory radiation-induced coronary artery disease: mapping the path and guiding treatment with optical coherence tomography.

Balanescu DV, Donisan T, Dayah T, Palaskas N, Lopez-Mattei J, Kim P, Pinnix CC, Moudgil R, Balanescu SM, Herrmann J, Cilingiroglu M, Marmagkiolis K, Iliescu C.

Int J Cardiovasc Imaging. 2019 May;35(5):759-760. doi: 10.1007/s10554-019-01533-9. Epub 2019 Feb 13. No abstract available.

PMID:
30758691
4.

A Cancer Paradox: Machine-Learning Backed Propensity-Score Analysis of Coronary Angiography Findings in Cardio-Oncology.

Balanescu DV, Monlezun DJ, Donisan T, Boone D, Cervoni-Curet F, Palaskas N, Lopez-Mattei J, Kim P, Iliescu C, Balanescu SM.

J Invasive Cardiol. 2019 Jan;31(1):21-26.

5.

Cardiovascular manifestations of Erdheim-Chester disease.

Ghotra AS, Thompson K, Lopez-Mattei J, Bawa D, Hernandez R, Banchs J, Palaskas N, Iliescu C, Kim P, Yusuf SW, Hassan SA.

Echocardiography. 2019 Feb;36(2):229-236. doi: 10.1111/echo.14231. Epub 2018 Dec 20.

PMID:
30569522
6.

Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib.

Sudasena D, Balanescu DV, Donisan T, Hassan S, Palaskas N, Kim P, Karimzad K, Lopez-Mattei J, Arain S, Gould KL, Iliescu C.

Cardiovasc Toxicol. 2018 Dec 12. doi: 10.1007/s12012-018-9499-2. [Epub ahead of print]

PMID:
30543051
7.

Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis.

Agha AM, Parwani P, Guha A, Durand JB, Iliescu CA, Hassan S, Palaskas NL, Gladish G, Kim PY, Lopez-Mattei J.

Open Heart. 2018 Sep 26;5(2):e000881. doi: 10.1136/openhrt-2018-000881. eCollection 2018. Review. Erratum in: Open Heart. 2018 Nov 21;5(2):e000881corr1.

8.

Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia.

Iliescu C, Balanescu DV, Donisan T, Giza DE, Muñoz Gonzalez ED, Cilingiroglu M, Song J, Mukerji SS, Lopez-Mattei JC, Kim PY, Palaskas N, Mouhayar EN, Durand JB, Marmagkiolis K.

Am J Cardiol. 2018 Nov 1;122(9):1465-1470. doi: 10.1016/j.amjcard.2018.07.033. Epub 2018 Aug 3.

PMID:
30180958
9.

Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art.

Pantuck M, Palaskas N, Drakaki A.

Cancer Treat Res Commun. 2018;17:8-12. doi: 10.1016/j.ctarc.2018.08.001. Epub 2018 Aug 22. Review. No abstract available.

PMID:
30173005
10.

Next generation T-cell therapy for genitourinary malignancies, part B: Overcoming obstacles and future strategies for success.

Pantuck M, Palaskas N, Drakaki A.

Cancer Treat Res Commun. 2018;17:1-7. doi: 10.1016/j.ctarc.2018.08.002. Epub 2018 Aug 17. Review. No abstract available.

PMID:
30170288
11.

Echocardiographic measures associated with the presence of left ventricular thrombus in patients with chemotherapy-related cardiac dysfunction.

Kitkungvan D, Yusuf SW, Moudgil R, Palaskas N, Guindani M, Juhee S, Hassan S, Sanchez L, Banchs J.

Echocardiography. 2018 Oct;35(10):1512-1518. doi: 10.1111/echo.14087. Epub 2018 Jul 13.

PMID:
30005128
12.

Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field.

Liu VY, Agha AM, Lopez-Mattei J, Palaskas N, Kim P, Thompson K, Mouhayar E, Marmagkiolis K, Hassan SA, Karimzad K, Iliescu CA.

Front Cardiovasc Med. 2018 May 17;5:48. doi: 10.3389/fcvm.2018.00048. eCollection 2018.

13.

Evolution of echocardiography in subclinical detection of cancer therapy-related cardiac dysfunction.

Moudgil R, Hassan S, Palaskas N, Lopez-Mattei J, Banchs J, Yusuf SW.

Echocardiography. 2018 Jun;35(6):860-868. doi: 10.1111/echo.14012. Epub 2018 May 11. Review.

PMID:
29749652
14.

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.

Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, Braas D, Grasso CS, Palaskas N, Ribas A, Graeber TG.

Cancer Cell. 2018 May 14;33(5):890-904.e5. doi: 10.1016/j.ccell.2018.03.017. Epub 2018 Apr 12.

15.

Evaluation and Management of Cardiac Tumors.

Palaskas N, Thompson K, Gladish G, Agha AM, Hassan S, Iliescu C, Kim P, Durand JB, Lopez-Mattei JC.

Curr Treat Options Cardiovasc Med. 2018 Mar 20;20(4):29. doi: 10.1007/s11936-018-0625-z. Review.

PMID:
29556752
16.

Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis.

Hassan SA, Palaskas N, Kim P, Iliescu C, Lopez-Mattei J, Mouhayar E, Mougdil R, Thompson K, Banchs J, Yusuf SW.

Curr Atheroscler Rep. 2018 Feb 8;20(2):10. doi: 10.1007/s11883-018-0702-5. Review.

PMID:
29423705
17.

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK.

Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.

18.

Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures.

Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, Larson SM, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG.

Mol Syst Biol. 2017 Feb 15;13(2):914. doi: 10.15252/msb.20167159.

19.

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA Jr, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A.

Cancer Discov. 2017 Feb;7(2):188-201. doi: 10.1158/2159-8290.CD-16-1223. Epub 2016 Nov 30.

20.

An Update on Gender Disparities in Coronary Heart Disease Care.

Shah T, Palaskas N, Ahmed A.

Curr Atheroscler Rep. 2016 May;18(5):28. doi: 10.1007/s11883-016-0574-5. Review.

PMID:
27029220
21.

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK.

Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.

22.

18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.

Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, Osborne JR, Linkov I, Kastenhuber ER, Taschereau R, Plaisier SB, Tran C, Heguy A, Wu H, Sander C, Phelps ME, Brennan C, Port E, Huse JT, Graeber TG, Mellinghoff IK.

Cancer Res. 2011 Aug 1;71(15):5164-74. doi: 10.1158/0008-5472.CAN-10-4633. Epub 2011 Jun 6.

23.

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.

Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK.

Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6459-64. doi: 10.1073/pnas.0911188107. Epub 2010 Mar 22.

24.

Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.

Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL.

Cancer Cell. 2007 Jun;11(6):555-69.

Supplemental Content

Loading ...
Support Center